Ascend Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Ascend Capital’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-11,028	Closed	-$501K	–	194
2017 Q1	$501K	Buy	+11,028	New	+$492K	0.02%	137

Other funds holding AERI

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ascend Capital's AERI Position: Q2 2017 in Review

Ascend Capital sold out of Aerie Pharmaceuticals (AERI) in Q2 2017, closing a stake of 11,028 shares — an estimated $501K sold.

Ascend Capital first reported a position in AERI in Q1 2017 and held it in 1 quarter. The position peaked at $501K in Q1 2017. 172 funds tracked by Wall St. Rank hold AERI as of Q2 2017.

Ascend Capital reported no remaining Aerie Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Ascend Capital sold 11,028 Aerie Pharmaceuticals shares in Q2 2017, an estimated $501K.
Ascend Capital first reported a position in Aerie Pharmaceuticals in Q1 2017 and held it in 1 quarter.
Ascend Capital's Aerie Pharmaceuticals position peaked at $501K in Q1 2017.
172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2017.

Based on Ascend Capital's 13F filing for Q2 2017, filed 11 Aug 2017.